Surrozen SRZN 深 滬
等待開盤 10-28 09:30:00 美东时间
29.53
+2.250
+8.25%
華盛通- 最 高30.35
- 今 開27.38
- 成交量 43.16万股
- 最 低 27.28
- 昨 收 27.28
- 總市值 3.47亿
- 52周最高 37.83
- 市盈率 靜 --
- 換手率 3.67%
- 52周最低 11.66
- 委 比 74.49%
- 總股本 1175.36万
- 歷史最高 210.00
- 量 比 0.82
- 振 幅 11.25%
- 歷史最低 4.50
- 每 手 1
- 風險率 4.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Surrozen Raises $95 Million, Extends Cash Runway
The latest announcement is out from Surrozen ( ($SRZN) ). On October 20, 2026, ...
10-21 05:29
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen, Inc. completed its second and final tranche of a private placement, raising approximately $95.1 million to strengthen its balance sheet and provide cash runway into 2029. The funds will support the advancement of SZN-8141 and SZN-8143, targeting retinal diseases. SZN-8141 combines Wnt agonism and VEGF antagonism for DME and wet AMD, while SZN-8143 adds IL-6 antagonism for broader retinal indications. The DUET Phase 1b/2a study for SZN-8...
10-20 20:59
Surrozen advances diabetic macular edema candidate into clinic after IND clearance
Surrozen (SRZN) on Friday announced plans to advance its bifunctional antibody SZN-8141 into clinical development for diabetic macular edema following the FDA clearance of its Investigational New Drug...
10-02 20:45
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen, Inc. announced the FDA clearance of its IND for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody for treating diabetic macular edema (DME). The first patient in the Phase 1b/2a DUET study is expected to be dosed in Q4 2026. This milestone triggers the second closing of Surrozen's March 2025 private placement, providing approximately $95.1 million to support the development of SZN-8141 and SZN-8143. SZN-8141 combines Wnt...
10-02 12:00
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
09-25 19:52
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema. The biotechnology company aims to advance the investigational therapy into clinic...
09-24 23:41
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Dru...
09-08 20:32
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and maintains $44 price target.
08-10 18:29
